Kurokawa, Kana
Mitsuishi, Yoichiro
Shimada, Naoko
Kawakami, Yuta
Miura, Keita
Miyawaki, Taichi
Asao, Tetsuhiko
Ko, Ryo
Shukuya, Takehito
Shibayama, Rina
Nojiri, Shuko
Takahashi, Kazuhisa
Article History
Received: 15 March 2022
Accepted: 27 September 2022
First Online: 6 October 2022
Declarations
:
: This study was approved by the institutional review board of Juntendo University Hospital (Approval number H18-0083) and was conducted in accordance with the Declaration of Helsinki. The institutional review board of Juntendo University Hospital waived the need of informed consent because of the study’s retrospective design.
: Not applicable.
: Yoichiro Mitsuishi reports grants from Takeda Pharmaceutical Company Limited, outside the submitted work. Tetsuhiko Asao reports honoraria from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K, MSD K.K, Nippon Boehringer Ingelheim Co., Ltd., ONO PHARMACEUTICAL CO., LTD., TAIHO PHARMACEUTICAL CO., LTD. and Takeda Pharmaceutical Company Limited, outside the submitted work. Ryo Ko reports grants and honoraria from MSD K.K, Nippon Boehringer Ingelheim Co., Ltd., TAIHO PHARMACEUTICAL CO., LTD., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K, Pfizer Inc. and AstraZeneca K.K., outside the submitted work. Takehito Shukuya reports grants and honoraria from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K, MSD K.K, TAIHO PHARMACEUTICAL CO., LTD., DAIICHI SANKYO Co., LTD., ONO PHARMACEUTICAL CO., LTD., Bristol-Myers Squibb Company, Nippon Kayaku Co.,Ltd. and Pfizer Inc., outside the submitted work. Kazuhisa Takahashi reports grants and honoraria from Chugai Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., MSD K.K, Glaxo SmithKline Consumer Healthcare Japan K.K, NIPPON SHINYAKU CO., LTD., TSUMURA & CO., Pfizer Inc., TAIHO PHARMACEUTICAL CO., LTD., DAIICHI SANKYO Co., LTD., Astellas Pharma Inc., KYORIN Pharmaceutical Co., Ltd., KYOWA Hakko Kirin Co., Ltd., TEIJIN PHARMA LIMITED, TEIJIN PHARMA LIMITED, Sanofi K.K., ONO PHARMACEUTICAL CO., LTD., Shionogi & Co., Ltd., Novartis Pharma K.K, Eli Lilly Japan K.K, Actelion Pharmaceuticals Japan Ltd., NIPRO PHARMA CORPORATION, Takeda Pharmaceutical Company Limited., Bayer Yakuhin, Ltd, Torii Pharmaceutical Co.,Ltd, AstraZeneca K.K., Bristol-Myers Squibb Company, Novartis Pharma K.K, Meiji Seika Pharma Co, Ltd., Abbott Japan LLC, outside the submitted work. The other authors have no conflicts of interest to declare.